Acrux patent triggers milestone payment
Friday, 19 November, 2004
Acrux (ASX:ACR) has received a US$250,000 milestone payment from its partner Vivus triggered by the granting of a US patent extending the coverage of its proprietary transdermal drug delivery system.
The patent provides protection for transdermal drug delivery systems consisting of an effective amount of a therapeutic drug, a dermal penetration enhancer and a volatile liquid, with an area of application that becomes touch-dry within 3 minutes of administration.
CEO Igor Gonda said the patent claims provided strategic protection for the product compared to other transdermal drug delivery systems including patches and gels. Acrux has similar patents pending in other international markets.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
